子宫肉瘤还是变性纤维瘤?验证新共识磁共振成像算法评估非典型子宫肿物的效能
本研究回顾性纳入2007年1月至2022年9月40例病理证实的非典型子宫肿物盆腔MRI,由两名放射科医师盲法独立使用2022年共识MRI流程图判断良恶性;两名读者判断良恶性的敏感度分别为75%和81.2%、特异度分别为95.8%和91.7%,读者间一致性kappa为0.89;排除非平滑肌肉瘤子宫恶性肿瘤后敏感度和阴性预测值均提高至100%。
要点
- 2022年共识MRI流程图判断非典型子宫肿物良恶性具有较好的特异度、敏感度、阳性预测值和阴性预测值。
- ADC值接近但未低于0.905×10⁻³ mm²/s时肿物仍可能为恶性,尤其在使用低于1000的b值时。
- 肿物以子宫内膜为主时,应依据T2加权及钆增强序列的形态学特征判断恶性可能。
核心结论
- 新共识盆腔MRI算法评估非典型子宫肿物判断恶性具有较好的特异度、敏感度、阳性预测值和阴性预测值,尤其对平滑肌肉瘤型子宫肉瘤;ADC值接近但未低于0.905×10⁻³ mm²/s时肿物仍可能为恶性,尤其使用低于1000的b值时;以子宫内膜为主的非典型子宫肿物,部分非平滑肌肉瘤子宫恶性肿瘤的ADC值可大于0.905×10⁻³ mm²/s,应依据T2及钆增强序列形态学特征判断。
研究设计与样本
- 回顾性研究,经病理证实的40例盆腔MRI检查(日期2007年1月至2022年9月),两名放射科医师盲法独立使用2022年共识非典型子宫肿物流程图判断肿物良恶性,评估的影像特征包括T2加权成像中/高信号强度、弥散加权成像高信号强度(高b值成像上信号等于或高于子宫内膜或淋巴结)、表观弥散系数(ADC)值≤0.905×10⁻³ mm²/s、腹膜转移及异常淋巴结。
关键影像表现/征象
- 评估的影像特征包括T2加权成像中/高信号强度、弥散加权成像高信号强度(高b值成像上信号等于或高于子宫内膜或淋巴结)、ADC值≤0.905×10⁻³ mm²/s、腹膜转移及异常淋巴结。
- 40例非典型子宫肿物中,24例为良性(22例平滑肌瘤、1例腺肌瘤、1例交界性卵巢肿瘤),16例为恶性(6例平滑肌肉瘤、6例癌肉瘤、2例子宫内膜间质肉瘤、1例高级别腺肉瘤、1例低级别子宫肉瘤)。
诊断标准与关键数值
- 读者1判断肿物良恶性的敏感度75%、特异度95.8%、阳性预测值92.3%、阴性预测值85%。
- 读者2判断肿物良恶性的敏感度81.2%、特异度91.7%、阳性预测值86.7%、阴性预测值88%。
- 两名读者间一致性kappa统计量为0.89。
- 排除非平滑肌肉瘤子宫恶性肿瘤后,敏感度和阴性预测值提高至100%。
- ADC值≤0.905×10⁻³ mm²/s为评估指标之一;ADC值接近但未低于0.905×10⁻³ mm²/s时肿物仍可能为恶性,尤其使用低于1000的b值时;部分非平滑肌肉瘤子宫恶性肿瘤的ADC值可大于0.905×10⁻³ mm²/s。
临床应用与阅片要点
- 使用2022年共识非典型子宫肿物MRI流程图判断肿物良恶性。
- ADC值接近但未低于0.905×10⁻³ mm²/s时,仍应警惕恶性可能,尤其当使用低于1000的b值时。
- 肿物以子宫内膜为主时,应依据T2加权及钆增强序列的形态学特征判断恶性可能,因部分非平滑肌肉瘤子宫恶性肿瘤的ADC值可大于0.905×10⁻³ mm²/s。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: The aim of the study is to assess the validity of a recently published consensus magnetic resonance imaging (MRI) diagnostic algorithm for differentiating degenerating leiomyomas from uterine sarcomas and other atypical appearing uterine malignancies.
METHODS: Atypical uterine masses on pelvic MRI were identified using a radiology report search engine and teaching files with the keywords "atypical leiomyoma," "atypical fibroid," and "sarcoma." All cases were pathology-proven. Two radiologists blinded to clinical, surgical, and pathologic reports retrospectively and independently reviewed 40 pelvic MRI examinations dated 1/2007-9/2022 to determine whether the masses appeared benign or malignant, using the 2022 consensus atypical uterine mass flow chart. Imaging features assessed included intermediate/high signal intensity (SI) at T2-weighted imaging, high diffusion weighted imaging SI (equal or higher SI than endometrium or lymph nodes on high b value imaging), apparent diffusion coefficient (ADC) value ≤0.905 × 10 -3 mm 2 /s, peritoneal metastases, and abnormal lymph nodes.
RESULTS: Among the 40 atypical uterine mass cases reviewed, 24 masses were benign (22 leiomyomas, 1 adenomyoma, and 1 borderline ovarian tumor) and 16 masses were malignant (6 leiomyosarcomas, 6 carcinosarcomas, 2 endometrial stromal sarcomas, 1 high-grade adenosarcoma, and 1 low-grade uterine sarcoma). Sensitivity, specificity, positive predictive value, and negative predictive value of whether a mass was benign or malignant were 75%, 95.8%, 92.3%, and 85% for reader 1, and 81.2%, 91.7%, 86.7%, and 88% for reader 2, respectively. Interrater agreement was strong, with a kappa statistic of 0.89. When excluding nonleiomyosarcoma uterine malignancies, sensitivity and negative predictive value improved to 100%.
CONCLUSIONS: The new consensus pelvic MRI algorithm for evaluating atypical uterine masses has good specificity, sensitivity, positive predictive value, and negative predictive value for determining malignancy, particularly for uterine sarcomas that are leiomyosarcomas. However, if ADC value is near but not below 0.905 × 10 -3 mm 2 /s, the mass may still be malignant, especially if a b value lower than 1000 is used. If the atypical uterine mass is predominantly endometrial, morphological features on T2 and postgadolinium sequences should guide suspicion, as some atypical appearing nonleiomyosarcoma uterine malignancies may have an ADC value greater than 0.905 × 10 -3 mm 2 /s.
引用
- Horowitz JM, Lopes Vendrami C, Velichko YS, et al. Uterine Sarcoma or Degenerating Fibroid? Validating the New Consensus Magnetic Resonance Imaging Algorithm for Evaluating Atypical Uterine Masses. J Comput Assist Tomogr. 2024. PMID: 39379060. doi:10.1097/RCT.0000000000001656
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。